Micksche M, Kokron O
Osterr Z Onkol. 1977;3(5-6):116-9.
In untreated patients with inoperable lung cancer, serum levels of alpha1-antitrypsin were found significantly increased in comparison to patients with non malignant diseases of the lung, alpha2-macroglobulin levels were unchanged in both groups of patients. There was also no difference in alpha2-macroglobulins in cancer patients reacting with DNCB and in non-reactors. Thus alpha2-macroglobulin levels do not seem to correlate with the immunestatus of cancer patients. Proteinase inhibitors are involved in a variety of biological processes including blood, clotting, digestion, and sperm capacitation. alpha1-antitrypsin, a alpha-globulin with a molecular weight of about 60,000 has been found to be decreased in patients' serum under several pathological conditions. A clear correlation exists between alpha1-antitrypsin deficiency and hereditary pulmonary emphysema (1, 2), respiratory distress syndrome (3), and juvenile cirrhoses of the liver (4). Elevated serum levels of alpha1-antitrypsin have also been found in some cancer cases. Thirty years ago a cancer test was developed on the basis of differences in the antiproteolytic activity in cancer patients' sera and in patients with other non-neoplastic diseases (5, 6). Several authors have tried to confirm these early data regarding specifity and sensitivity with respect to a screening test for cancer (7, 8). Methods of these authors were based mainly on enzyme substrate inhibition assays by addition of the patients' sera. Recently a commercially available test, based on immune-precipitation according to Mancini (9), has been developed (Behring-Werke, Partigen). By using this standardized method for determinating alpha1-antitrypsin, Harris et al. have recently demonstrated that patients with inoperable lung cancer have significantly elevated levels of this antiprotease in their sera (10), in comparison to patients with non malignant diseases of the lung. alpha2-macroglobulin is a serum protein with a molecular weight of 800,000 and with known antiprotease activity and can therefore bind trypsin, plasmin, elastase, and collagenase and it is known that alpha2-macroglobulin decreases with increasing of age. Changes of alpha-macroglobulin have also been observed in several pathological conditions (11). James et al. 4ave found decreases in serum of myeloma patients (12). An association between the development and function of lymphocytes and alpha2-macroglobulin has been suggested by several authors (13, 14). This alpha2-globulin has also been demonstrated on the surface of peripheral blood lymphocytes (15) and there is evidence that it is synthesized by lymphocytes (16). The purpose of the present study was to determine serum alpha1-antitrypsin levels in patients with inoperable lung cancer and to determine whether there is also an inverse correlation to alpha2-macroglobulin. It was further attempted to correlate alpha2-macroglobulin with general immunological parameters, as it is known that patients with lung cancer show a decreased general immune-reactivity (17).
在未经治疗的无法手术的肺癌患者中,与患有肺部非恶性疾病的患者相比,发现血清α1 -抗胰蛋白酶水平显著升高,两组患者的α2 -巨球蛋白水平均未改变。在对二硝基氯苯有反应和无反应的癌症患者中,α2 -巨球蛋白水平也没有差异。因此,α2 -巨球蛋白水平似乎与癌症患者的免疫状态无关。蛋白酶抑制剂参与多种生物学过程,包括血液凝固、消化和精子获能。α1 -抗胰蛋白酶是一种分子量约为60,000的α球蛋白,已发现在几种病理情况下患者血清中其水平会降低。α1 -抗胰蛋白酶缺乏与遗传性肺气肿(1,2)、呼吸窘迫综合征(3)和青少年肝硬化(4)之间存在明显相关性。在一些癌症病例中也发现血清α1 -抗胰蛋白酶水平升高。三十年前,基于癌症患者血清和其他非肿瘤性疾病患者血清中抗蛋白水解活性的差异开发了一种癌症检测方法(5,6)。几位作者试图证实这些关于癌症筛查试验特异性和敏感性的早期数据(7,8)。这些作者的方法主要基于加入患者血清后的酶底物抑制试验。最近,一种基于曼奇尼免疫沉淀法(9)的商用检测方法(贝林 - 韦尔克公司的Partigen)已被开发出来。通过使用这种标准化方法测定α1 -抗胰蛋白酶,哈里斯等人最近证明,与患有肺部非恶性疾病的患者相比,无法手术的肺癌患者血清中这种抗蛋白酶水平显著升高(10)。α2 -巨球蛋白是一种分子量为800,000的血清蛋白,具有已知的抗蛋白酶活性,因此可以结合胰蛋白酶、纤溶酶、弹性蛋白酶和胶原酶,并且已知α2 -巨球蛋白会随着年龄的增长而降低。在几种病理情况下也观察到了α -巨球蛋白的变化(11)。詹姆斯等人发现骨髓瘤患者血清中α2 -巨球蛋白水平降低(12)。几位作者提出淋巴细胞的发育和功能与α2 -巨球蛋白之间存在关联(13,14)。这种α2 -球蛋白也已在外周血淋巴细胞表面得到证实(15),并且有证据表明它是由淋巴细胞合成的(16)。本研究的目的是测定无法手术的肺癌患者的血清α1 -抗胰蛋白酶水平,并确定其与α2 -巨球蛋白是否也存在负相关。还进一步尝试将α2 -巨球蛋白与一般免疫学参数相关联,因为已知肺癌患者的一般免疫反应性会降低(17)。